Monash IVF Group 향후 성장

Future 기준 점검 0/6

Monash IVF Group 의 수익은 연간 0.8% 감소할 것으로 예상되는 반면, 연간 수익은 1.4% 로 증가할 것으로 예상됩니다. EPS는 연간 0.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.1% 로 예상됩니다.

핵심 정보

-0.8%

이익 성장률

0.32%

EPS 성장률

Healthcare 이익 성장	18.8%
매출 성장률	1.4%
향후 자기자본이익률	9.11%
애널리스트 커버리지	Good
마지막 업데이트	24 Nov 2025

최근 향후 성장 업데이트

Recent updates

Subdued Growth No Barrier To Monash IVF Group Limited's (ASX:MVF) Price

Nov 13

Is Monash IVF Group (ASX:MVF) A Risky Investment?

Aug 22

Benign Growth For Monash IVF Group Limited (ASX:MVF) Underpins Stock's 26% Plummet

Jun 17

Monash IVF Group (ASX:MVF) Seems To Use Debt Quite Sensibly

May 20

Monash IVF Group Limited's (ASX:MVF) Popularity With Investors Under Threat As Stock Sinks 26%

Apr 29

Shareholders Will Probably Not Have Any Issues With Monash IVF Group Limited's (ASX:MVF) CEO Compensation

Nov 04

Monash IVF Group's (ASX:MVF) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Be Wary Of Monash IVF Group (ASX:MVF) And Its Returns On Capital

May 14

Should You Think About Buying Monash IVF Group Limited (ASX:MVF) Now?

Jun 06

Monash IVF Group (ASX:MVF) May Have Issues Allocating Its Capital

May 25

Is Monash IVF Group Limited (ASX:MVF) Expensive For A Reason? A Look At Its Intrinsic Value

May 13

Is Monash IVF Group Limited (ASX:MVF) A Smart Choice For Dividend Investors?

Mar 14

Just Four Days Till Monash IVF Group Limited (ASX:MVF) Will Be Trading Ex-Dividend

Mar 04

Monash IVF Group Limited (ASX:MVF) Just Released Its Half-Year Results And Analysts Are Updating Their Estimates

Feb 26

Is Now An Opportune Moment To Examine Monash IVF Group Limited (ASX:MVF)?

Feb 15

A Look At The Fair Value Of Monash IVF Group Limited (ASX:MVF)

Feb 03

We're Not So Sure You Should Rely on Monash IVF Group's (ASX:MVF) Statutory Earnings

Jan 22

Is Monash IVF Group Limited (ASX:MVF) Popular Amongst Institutions?

Jan 10

Is Monash IVF Group (ASX:MVF) Using Too Much Debt?

Dec 28

What Do The Returns On Capital At Monash IVF Group (ASX:MVF) Tell Us?

Dec 17

Monash IVF Group's (ASX:MVF) Shareholders Are Down 56% On Their Shares

Dec 06

Monash IVF Group Limited's (ASX:MVF) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?

Nov 24

이익 및 매출 성장 예측

ASX:MVF - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
6/30/2028	281	23	29	52	7
6/30/2027	270	21	26	48	7
6/30/2026	261	18	27	42	7
6/30/2025	272	25	-2	13	N/A
3/31/2025	271	11	5	21	N/A
12/31/2024	270	-2	12	29	N/A
9/30/2024	263	-4	22	41	N/A
6/30/2024	255	-7	31	53	N/A
3/31/2024	246	9	27	51	N/A
12/31/2023	236	24	22	49	N/A
9/30/2023	225	23	17	44	N/A
6/30/2023	214	22	11	39	N/A
3/31/2023	204	19	11	36	N/A
12/31/2022	195	17	11	33	N/A
9/30/2022	193	18	16	32	N/A
6/30/2022	192	18	20	32	N/A
3/31/2022	193	21	25	35	N/A
12/31/2021	194	23	30	38	N/A
9/30/2021	189	24	32	41	N/A
6/30/2021	184	25	34	44	N/A
3/31/2021	171	22	33	43	N/A
12/31/2020	159	18	31	41	N/A
9/30/2020	152	15	27	36	N/A
6/30/2020	145	12	24	31	N/A
3/31/2020	149	15	22	30	N/A
12/31/2019	152	18	20	28	N/A
9/30/2019	152	19	23	31	N/A
6/30/2019	152	20	27	33	N/A
3/31/2019	151	19	N/A	31	N/A
12/31/2018	151	19	N/A	29	N/A
9/30/2018	151	20	N/A	28	N/A
6/30/2018	151	21	N/A	26	N/A
3/31/2018	152	24	N/A	N/A	N/A
12/31/2017	153	26	N/A	29	N/A
9/30/2017	154	28	N/A	28	N/A
6/30/2017	155	30	N/A	26	N/A
3/31/2017	156	30	N/A	N/A	N/A
12/31/2016	156	30	N/A	34	N/A
9/30/2016	156	29	N/A	39	N/A
6/30/2016	157	29	N/A	44	N/A
3/31/2016	150	27	N/A	41	N/A
12/31/2015	144	24	N/A	38	N/A
9/30/2015	134	23	N/A	37	N/A
6/30/2015	125	21	N/A	36	N/A
3/31/2015	121	15	N/A	37	N/A
12/31/2014	117	8	N/A	38	N/A

애널리스트 향후 성장 전망

수입 대 저축률: MVF 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.8%).

수익 vs 시장: MVF 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.8%).

고성장 수익: MVF 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: MVF 의 수익(연간 1.4%)이 Australian 시장(연간 5.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: MVF 의 수익(연간 1.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MVF의 자본 수익률은 3년 후 9.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/25 09:49
종가	2025/11/25 00:00
수익	2025/06/30
연간 수익	2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Monash IVF Group Limited는 12명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Bradley Watson	Bell Potter
Martyn Jacobs	Bell Potter
Tara Speranza	Bell Potter

Monash IVF Group 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 12% to AU$0.94

Price target decreased by 8.3% to AU$1.01

Price target decreased by 11% to AU$1.16

Price target decreased by 8.1% to AU$1.40

Price target increased by 7.3% to AU$1.42

Consensus forecasts updated

Recent updates

WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.

New major risk - Revenue and earnings growth

Subdued Growth No Barrier To Monash IVF Group Limited's (ASX:MVF) Price

Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025

New major risk - Revenue and earnings growth

Price target decreased by 12% to AU$0.94

New major risk - Revenue and earnings growth

Is Monash IVF Group (ASX:MVF) A Risky Investment?

Price target decreased by 8.3% to AU$1.01

Full year 2025 earnings released: EPS: AU$0.064 (vs AU$0.017 loss in FY 2024)

New major risk - Revenue and earnings growth

Benign Growth For Monash IVF Group Limited (ASX:MVF) Underpins Stock's 26% Plummet

Monash IVF Group Limited Announces CEO Changes

New minor risk - Share price stability

Price target decreased by 11% to AU$1.16

Monash IVF Group (ASX:MVF) Seems To Use Debt Quite Sensibly

Monash IVF Group Limited's (ASX:MVF) Popularity With Investors Under Threat As Stock Sinks 26%

Price target decreased by 8.1% to AU$1.40

Monash IVF Group (ASX:MVF) Is Increasing Its Dividend To A$0.026

First half 2025 earnings: EPS and revenues exceed analyst expectations

First half dividend increased to AU$0.026

Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025

Monash IVF Group Limited to Report Fiscal Year 2025 Results on Aug 22, 2025

Smallcap takeover in niche industry

Monash IVF Group Limited Announces Board Changes

Independent Non-Executive Director recently bought AU$93k worth of stock

Monash IVF Group's (ASX:MVF) Dividend Will Be A$0.025

Monash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024

Full year 2024 earnings: EPS misses analyst expectations

Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.

Upcoming dividend of AU$0.025 per share

Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024

First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)

Monash IVF Group's (ASX:MVF) Dividend Will Be A$0.025

First half dividend of AU$0.025 announced

Monash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024

Price target increased by 7.3% to AU$1.42

Upcoming dividend of AU$0.022 per share at 3.5% yield

Monash IVF Group (ASX:MVF) Will Pay A Dividend Of A$0.022

Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Monash IVF Group Limited Provides Update on Class Action Lawsuit

Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.

Upcoming dividend of AU$0.022 per share at 4.2% yield

First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)

Monash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023

Here's What's Concerning About Monash IVF Group's (ASX:MVF) Returns On Capital

Insufficient new directors

Shareholders Will Probably Not Have Any Issues With Monash IVF Group Limited's (ASX:MVF) CEO Compensation

Monash IVF Group Limited (ASX:MVF) completed the acquisition of ART Associates Queensland #2 Pty Ltd.

Consensus forecasts updated

Upcoming dividend of AU$0.022 per share

Monash IVF Group's (ASX:MVF) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2022 earnings: EPS misses analyst expectations

Monash IVF Group Limited Announces Ordinary Fully Paid Distribution for the Six Months Ended June 30, 2022, Payable on October 7, 2022

Monash IVF Group Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Monash IVF Group Limited, Annual General Meeting, Nov 11, 2022

Insufficient new directors

Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million.

Consensus EPS estimates fall by 16%

Be Wary Of Monash IVF Group (ASX:MVF) And Its Returns On Capital

Consensus EPS estimates fall by 10%

Insufficient new directors

Monash IVF Group Limited Announces Fully Franked Distribution for the Six Months That Ended December 31, 2021, Payable on April 4, 2022

Monash IVF Group Limited to Report First Half, 2022 Results on Feb 17, 2022

Monash IVF Group Limited Updates Temporary Suspension of IVF Procedures Lifted in Victoria

Upcoming dividend of AU$0.021 per share

Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)

Price target increased to AU$1.08